Non-Hodgkin’s Lymphomas, Version 2.2014

Restricted access

Non-Hodgkin’s lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for approximately 22% of all newly diagnosed cases of NHL. The incorporation of rituximab to chemotherapy regimens has become a widely accepted standard of care for first-line therapy for patients with FL. Maintenance and consolidation therapy with rituximab and radioimmunotherapy have also been associated with improved progression-free survival in patients experiencing response to first-line therapy. Despite therapeutic advances that have improved outcomes, FL is generally considered a chronic disease characterized by multiple recurrences with current therapies. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with FL.

  • 1.

    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:929.

  • 2.

    Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000;92:12401251.

    • Search Google Scholar
    • Export Citation
  • 3.

    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 1997;89:39093918.

    • Search Google Scholar
    • Export Citation
  • 4.

    Koster A, Tromp HA, Raemaekers JM. The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma. Haematologica 2007;92:184190.

    • Search Google Scholar
    • Export Citation
  • 5.

    Wang SA, Wang L, Hochberg EP. Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features. Am J Surg Pathol 2005;29:14901496.

    • Search Google Scholar
    • Export Citation
  • 6.

    Solal-Celigny P, Roy P, Colombat P. Follicular lymphoma international prognostic index. Blood 2004;104:12581265.

  • 7.

    Friedberg JW, Taylor MD, Cerhan JR. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009;27:12021208.

    • Search Google Scholar
    • Export Citation
  • 8.

    Federico M, Bellei M, Marcheselli L. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:45554562.

    • Search Google Scholar
    • Export Citation
  • 9.

    Press OW, Unger JM, Rimsza LM. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 2013;31:314320.

    • Search Google Scholar
    • Export Citation
  • 10.

    Press OW, Unger JM, Rimsza LM. A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine-tositumomab. Clin Cancer Res 2013;19:66246632.

    • Search Google Scholar
    • Export Citation
  • 11.

    Cong P, Raffeld M, Teruya-Feldstein J. In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. Blood 2002;99:33763382.

    • Search Google Scholar
    • Export Citation
  • 12.

    Harris NL, Swerdlow SH, Jaffe ES. Follicular lymphoma. In: Swerdlow SH, Campo E, Harris NL, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008:220226.

    • Search Google Scholar
    • Export Citation
  • 13.

    Carbone A, Gloghini A, Santoro A. In situ follicular lymphoma: pathologic characteristics and diagnostic features. Hematol Oncol 2012;30:17.

    • Search Google Scholar
    • Export Citation
  • 14.

    Sotomayor EA, Shah IM, Sanger WG, Mark HF. In situ follicular lymphoma with a 14;18 translocation diagnosed by a multimodal approach. Exp Mol Pathol 2007;83:254258.

    • Search Google Scholar
    • Export Citation
  • 15.

    Henopp T, Quintanilla-Martinez L, Fend F, Adam P. Prevalence of follicular lymphoma in situ in consecutively analysed reactive lymph nodes. Histopathology 2011;59:139142.

    • Search Google Scholar
    • Export Citation
  • 16.

    Jegalian AG, Eberle FC, Pack SD. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood 2011;118:29762984.

    • Search Google Scholar
    • Export Citation
  • 17.

    Pillai RK, Surti U, Swerdlow SH. Follicular lymphoma-like B-cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies. Haematologica 2013;98:15711580.

    • Search Google Scholar
    • Export Citation
  • 18.

    Bonzheim I, Salaverria I, Haake A. A unique case of follicular lymphoma provides insights to the clonal evolution from follicular lymphoma in situ to manifest follicular lymphoma. Blood 2011;118:34423444.

    • Search Google Scholar
    • Export Citation
  • 19.

    Frizzera G, Murphy SB. Follicular (nodular) lymphoma in childhood: a rare clinical-pathological entity. Report of eight cases from four cancer centers. Cancer 1979;44:22182235.

    • Search Google Scholar
    • Export Citation
  • 20.

    Lorsbach RB, Shay-Seymore D, Moore J. Clinicopathologic analysis of follicular lymphoma occurring in children. Blood 2002;99:19591964.

  • 21.

    Oschlies I, Salaverria I, Mahn F. Pediatric follicular lymphoma—a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin’s Lymphoma— Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials. Haematologica 2010;95:253259.

    • Search Google Scholar
    • Export Citation
  • 22.

    Ribeiro RC, Pui CH, Murphy SB. Childhood malignant non-Hodgkin lymphomas of uncommon histology. Leukemia 1992;6:761765.

  • 23.

    Liu Q, Salaverria I, Pittaluga S. Follicular lymphomas in children and young adults: a comparison of the pediatric variant with usual follicular lymphoma. Am J Surg Pathol 2013;37:333343.

    • Search Google Scholar
    • Export Citation
  • 24.

    Louissaint A Jr, Ackerman AM, Dias-Santagata D. Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement. Blood 2012;120:23952404.

    • Search Google Scholar
    • Export Citation
  • 25.

    Kumar R, Galardy PJ, Dogan A. Rituximab in combination with multiagent chemotherapy for pediatric follicular lymphoma. Pediatr Blood Cancer 2011;57:317320.

    • Search Google Scholar
    • Export Citation
  • 26.

    Bain BJ. Bone marrow trephine biopsy. J Clin Pathol 2001;54:737742.

  • 27.

    Bishop PW, McNally K, Harris M. Audit of bone marrow trephines. J Clin Pathol 1992;45:11051108.

  • 28.

    Schoder H, Noy A, Gonen M. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2005;23:46434651.

    • Search Google Scholar
    • Export Citation
  • 29.

    Campbell BA, Voss N, Woods R. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer 2010;116:37973806.

    • Search Google Scholar
    • Export Citation
  • 30.

    Guadagnolo BA, Li S, Neuberg D. Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 2006;64:928934.

    • Search Google Scholar
    • Export Citation
  • 31.

    Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996;14:12821290.

    • Search Google Scholar
    • Export Citation
  • 32.

    Wilder RB, Jones D, Tucker SL. Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001;51:12191227.

    • Search Google Scholar
    • Export Citation
  • 33.

    Advani R, Rosenberg S, Horning S. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004;22:14541459.

    • Search Google Scholar
    • Export Citation
  • 34.

    McLaughlin P, Fuller L, Redman J. Stage I-II low-grade lymphomas: a prospective trial of combination chemotherapy and radiotherapy. Ann Oncol 1991;2(Suppl 2):137140.

    • Search Google Scholar
    • Export Citation
  • 35.

    Yahalom J, Varsos G, Fuks Z. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer 1993;71:23422350.

    • Search Google Scholar
    • Export Citation
  • 36.

    Friedberg JW, Byrtek M, Link BK. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol 2012;30:33683375.

    • Search Google Scholar
    • Export Citation
  • 37.

    Michallet AS, Lebras LL, Bauwens DD. Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy? J Hematol Oncol 2013;6:45.

    • Search Google Scholar
    • Export Citation
  • 38.

    Young RC, Longo DL, Glatstein E. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 1988;25:1116.

    • Search Google Scholar
    • Export Citation
  • 39.

    Brice P, Bastion Y, Lepage E. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1997;15:11101117.

    • Search Google Scholar
    • Export Citation
  • 40.

    Ardeshna KM, Smith P, Norton A. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003;362:516522.

    • Search Google Scholar
    • Export Citation
  • 41.

    Ardeshna K, Qian W, Smith P. An Intergroup randomized trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis [abstract]. Blood 2010;116:Abstact 6.

    • Search Google Scholar
    • Export Citation
  • 42.

    Kahl BS, Hong F, Williams ME. Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma [abstract]. Blood 2011;118:Abstract LBA-6.

    • Search Google Scholar
    • Export Citation
  • 43.

    Solal-Celigny P, Bellei M, Marcheselli L. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol 2012;30:38483853.

    • Search Google Scholar
    • Export Citation
  • 44.

    Colombat P, Salles G, Brousse N. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001;97:101106.

    • Search Google Scholar
    • Export Citation
  • 45.

    Witzig TE, Vukov AM, Habermann TM. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005;23:11031108.

    • Search Google Scholar
    • Export Citation
  • 46.

    McLaughlin P, Grillo-Lopez AJ, Link BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:28252833.

    • Search Google Scholar
    • Export Citation
  • 47.

    Czuczman MS, Grillo-Lopez AJ, White CA. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268276.

    • Search Google Scholar
    • Export Citation
  • 48.

    Czuczman MS, Weaver R, Alkuzweny B. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22:47114716.

    • Search Google Scholar
    • Export Citation
  • 49.

    Hiddemann W, Kneba M, Dreyling M. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:37253732.

    • Search Google Scholar
    • Export Citation
  • 50.

    Marcus R, Imrie K, Belch A. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:14171423.

    • Search Google Scholar
    • Export Citation
  • 51.

    Marcus R, Imrie K, Solal-Celigny P. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:45794586.

    • Search Google Scholar
    • Export Citation
  • 52.

    Schulz H, Bohlius JF, Trelle S. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706714.

    • Search Google Scholar
    • Export Citation
  • 53.

    Buske C, Kneba M, Lengfelder E. Front-line combined immuno-chemotherapy (R-CHOP) significantly improves the time to treatment failure and overall survival in elderly patients with advanced stage follicular lymphoma: results of a prospective randomized trial of the german low grade lymphoma study group (GLSG) [abstract]. Blood 2006;108:Abstract 482.

    • Search Google Scholar
    • Export Citation
  • 54.

    Czuczman MS, Koryzna A, Mohr A. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005;23:694704.

    • Search Google Scholar
    • Export Citation
  • 55.

    Forstpointner R, Dreyling M, Repp R. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:30643071.

    • Search Google Scholar
    • Export Citation
  • 56.

    McLaughlin P, Hagemeister FB, Rodriguez MA. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 2000;27:3741.

    • Search Google Scholar
    • Export Citation
  • 57.

    Zinzani PL, Pulsoni A, Perrotti A. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004;22:26542661.

    • Search Google Scholar
    • Export Citation
  • 58.

    Liu Q, Fayad L, Cabanillas F. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006;24:15821589.

    • Search Google Scholar
    • Export Citation
  • 59.

    Morschhauser F, Mounier N, Sebban C. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d’Etude des Lymphomes de l’Adulte (GELA) and Groupe Ouest Est des Leucemies et Autres Maladies du Sang (GOELAMS). Cancer 2010;116:42994308.

    • Search Google Scholar
    • Export Citation
  • 60.

    Nastoupil L, Sinha R, Byrtek M. A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (FL) used in the United States [abstract]. Blood 2011;118:Abstract 97.

    • Search Google Scholar
    • Export Citation
  • 61.

    Federico M, Luminari S, Dondi A. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 2013;31:15061513.

    • Search Google Scholar
    • Export Citation
  • 62.

    Kalaycio M, Rybicki L, Pohlman B. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol 2006;24:36043610.

    • Search Google Scholar
    • Export Citation
  • 63.

    Ketterer N, Salles G, Moullet I. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998;103:235242.

    • Search Google Scholar
    • Export Citation
  • 64.

    Micallef IN, Apostolidis J, Rohatiner AZ. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin’s lymphoma. Hematol J 2000;1:367373.

    • Search Google Scholar
    • Export Citation
  • 65.

    Fowler N, Kahl BS, Lee P. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol 2011;29:33893395.

    • Search Google Scholar
    • Export Citation
  • 66.

    Friedberg JW, Vose JM, Kelly JL. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117:28072812.

    • Search Google Scholar
    • Export Citation
  • 67.

    Friedberg JW, Cohen P, Chen L. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204210.

    • Search Google Scholar
    • Export Citation
  • 68.

    Kahl BS, Bartlett NL, Leonard JP. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 2010;116:106114.

    • Search Google Scholar
    • Export Citation
  • 69.

    Robinson KS, Williams ME, van der Jagt RH. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol 2008;26:44734479.

    • Search Google Scholar
    • Export Citation
  • 70.

    Rummel MJ, Kaiser U, Balser C. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas - final results of the randomized phase III study NHL 2-2003 on behalf of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. Blood 2010;116:Abstract 856.

    • Search Google Scholar
    • Export Citation
  • 71.

    Rummel MJ, Niederle N, Maschmeyer G. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:12031210.

    • Search Google Scholar
    • Export Citation
  • 72.

    Flinn IW, Van der Jagt RH, Kahl BS. An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin’s lymphoma (NHL) or mantle cell lymphoma (MCL): the Bright study [abstract]. Blood 2012;120:Abstract 902.

    • Search Google Scholar
    • Export Citation
  • 73.

    Witzig TE, Wiernik PH, Moore T. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma. J Clin Oncol 2009;27:54045409.

    • Search Google Scholar
    • Export Citation
  • 74.

    Leonard J, Jung SH, Johnson JL. CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 8000.

    • Search Google Scholar
    • Export Citation
  • 75.

    Fowler NH, Neelapu SS, Hagemeister FB. Lenalidomide and rituximab for untreated indolent lymphoma: final results of a phase II study [abstract]. Blood 2012;120:Abstract 901.

    • Search Google Scholar
    • Export Citation
  • 76.

    Witzig TE, Flinn IW, Gordon LI. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 2002;20:32623269.

    • Search Google Scholar
    • Export Citation
  • 77.

    Witzig TE, Gordon LI, Cabanillas F. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002;20:24532463.

    • Search Google Scholar
    • Export Citation
  • 78.

    Gordon LI, Witzig T, Molina A. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 2004;5:98101.

    • Search Google Scholar
    • Export Citation
  • 79.

    Scholz CW, Pinto A, Linkesch W. 90Yttrium ibritumomab tiuxetan as first line treatment for follicular lymphoma. first results from an international phase II clinical trial [abstract]. Blood 2010;116:Abstract 593.

    • Search Google Scholar
    • Export Citation
  • 80.

    Scholz CW, Pinto A, Linkesch W. (90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol 2013;31:308313.

    • Search Google Scholar
    • Export Citation
  • 81.

    Kaminski MS, Tuck M, Estes J. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441449.

  • 82.

    Vose JM, Wahl RL, Saleh M. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2000;18:13161323.

    • Search Google Scholar
    • Export Citation
  • 83.

    Kaminski MS, Zelenetz AD, Press OW. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2001;19:39183328.

    • Search Google Scholar
    • Export Citation
  • 84.

    Horning SJ, Younes A, Jain V. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005;23:712719.

    • Search Google Scholar
    • Export Citation
  • 85.

    Kaminski MS, Tuck M, Estes J. Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage, follicular lymphoma: median 10 year follow-up results [abstract]. Blood 2009;114:Abstract 3759.

    • Search Google Scholar
    • Export Citation
  • 86.

    Kaminski MS, Zelenetz AD, Press OW. Tositumomab and I 131 tositumomab achieves complete remissions lasting > 10 years in patients with chemotherapy-refractory low-grade and transformed B-cell lymphomas [abstract]. Blood 2010;116:Abstract 3960.

    • Search Google Scholar
    • Export Citation
  • 87.

    Hainsworth JD, Spigel DR, Markus TM. Rituximab plus short-duration chemotherapy followed by yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma 2009;9:223228.

    • Search Google Scholar
    • Export Citation
  • 88.

    Jacobs SA, Swerdlow SH, Kant J. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 2008;14:70887094.

    • Search Google Scholar
    • Export Citation
  • 89.

    Morschhauser F, Radford J, Van Hoof A. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:51565164.

    • Search Google Scholar
    • Export Citation
  • 90.

    Zinzani PL, Tani M, Pulsoni A. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol 2008;9:352358.

    • Search Google Scholar
    • Export Citation
  • 91.

    Leonard JP, Coleman M, Kostakoglu L. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23:56965704.

    • Search Google Scholar
    • Export Citation
  • 92.

    Press OW, Unger JM, Braziel RM. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:41434149.

    • Search Google Scholar
    • Export Citation
  • 93.

    Press OW, Unger JM, Braziel RM. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003;102:16061612.

    • Search Google Scholar
    • Export Citation
  • 94.

    Link BK, Martin P, Kaminski MS. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol 2010;28:30353041.

    • Search Google Scholar
    • Export Citation
  • 95.

    Morschhauser F, Radford J, Van Hoof A. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III First-Line Indolent Trial. J Clin Oncol 2013;31:19771983.

    • Search Google Scholar
    • Export Citation
  • 96.

    Ghielmini M, Schmitz SH, Cogliatti SB. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103:44164423.

    • Search Google Scholar
    • Export Citation
  • 97.

    Martinelli G, Hsu Schmitz SF, Utiger U. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010;28:44804484.

    • Search Google Scholar
    • Export Citation
  • 98.

    Taverna CJ, Bassi S, Hitz F. Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35/03. Blood 2010;116:1802.

    • Search Google Scholar
    • Export Citation
  • 99.

    Hainsworth JD, Litchy S, Shaffer DW. Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin’s lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23:10881095.

    • Search Google Scholar
    • Export Citation
  • 100.

    Hochster H, Weller E, Gascoyne RD. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009;27:16071614.

    • Search Google Scholar
    • Export Citation
  • 101.

    Salles G, Seymour JF, Offner F. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:4251.

    • Search Google Scholar
    • Export Citation
  • 102.

    Forstpointner R, Unterhalt M, Dreyling M. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:40034008.

    • Search Google Scholar
    • Export Citation
  • 103.

    van Oers MH, Klasa R, Marcus RE. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:32953301.

    • Search Google Scholar
    • Export Citation
  • 104.

    van Oers MH, Van Glabbeke M, Giurgea L. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:28532858.

    • Search Google Scholar
    • Export Citation
  • 105.

    Freedman AS, Neuberg D, Mauch P. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999;94:33253333.

    • Search Google Scholar
    • Export Citation
  • 106.

    Rohatiner AZ, Nadler L, Davies AJ. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007;25:25542559.

    • Search Google Scholar
    • Export Citation
  • 107.

    Schouten HC, Qian W, Kvaloy S. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003;21:39183927.

    • Search Google Scholar
    • Export Citation
  • 108.

    Sebban C, Brice P, Delarue R. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008;26:36143620.

    • Search Google Scholar
    • Export Citation
  • 109.

    Peniket AJ, Ruiz de Elvira MC, Taghipour G. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003;31:667678.

    • Search Google Scholar
    • Export Citation
  • 110.

    van Besien K, Loberiza FR, Bajorunaite R. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003;102:35213529.

    • Search Google Scholar
    • Export Citation
  • 111.

    Hari P, Carreras J, Zhang MJ. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008;14:236245.

    • Search Google Scholar
    • Export Citation
  • 112.

    Bishu S, Quigley JM, Bishu SR. Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma 2007;48:15481555.

    • Search Google Scholar
    • Export Citation
  • 113.

    Blum RH, Seymour JF, Wirth A. Frequent impact of [18F] fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin’s lymphoma. Clin Lymphoma 2003;4:4349.

    • Search Google Scholar
    • Export Citation
  • 114.

    Karam M, Novak L, Cyriac J. Role of fluorine-18 fluorodeoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006;107:175183.

    • Search Google Scholar
    • Export Citation
  • 115.

    Wohrer S, Jaeger U, Kletter K. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006;17:780784.

    • Search Google Scholar
    • Export Citation
  • 116.

    Janikova A, Bolcak K, Pavlik T. Value of [18F] fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma? Clin Lymphoma Myeloma 2008;8:287293.

    • Search Google Scholar
    • Export Citation
  • 117.

    Zinzani PL, Musuraca G, Alinari L. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma 2007;7:291295.

    • Search Google Scholar
    • Export Citation
  • 118.

    Le Dortz L, De Guibert S, Bayat S. Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging 2010;37:23072314.

    • Search Google Scholar
    • Export Citation
  • 119.

    Trotman J, Fournier M, Lamy T. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 2011;29:31943200.

    • Search Google Scholar
    • Export Citation
  • 120.

    Dupuis J, Berriolo-Riedinger A, Julian A. Impact of [(18) F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS. J Clin Oncol 2012;30:43174322.

    • Search Google Scholar
    • Export Citation
  • 121.

    Noy A, Schoder H, Gonen M. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol 2009;20:508512.

    • Search Google Scholar
    • Export Citation
  • 122.

    Oh YK, Ha CS, Samuels BI. Stages I-III follicular lymphoma: role of CT of the abdomen and pelvis in follow-up studies. Radiology 1999;210:483486.

    • Search Google Scholar
    • Export Citation
  • 123.

    Zinzani PL, Stefoni V, Tani M. Role of [18F] fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009;27:17811787.

    • Search Google Scholar
    • Export Citation
  • 124.

    Peterson BA, Petroni GR, Frizzera G. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 2003;21:515.

    • Search Google Scholar
    • Export Citation
  • 125.

    Al-Tourah AJ, Gill KK, Chhanabhai M. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol 2008;26:51655169.

    • Search Google Scholar
    • Export Citation
  • 126.

    Yuen AR, Kamel OW, Halpern J, Horning SJ. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 1995;13:17261733.

    • Search Google Scholar
    • Export Citation
  • 127.

    Villa D, Crump M, Panzarella T. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian Blood and Marrow Transplant group. J Clin Oncol 2013;31:11641171.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 236 191 16
PDF Downloads 71 57 5
EPUB Downloads 0 0 0